Journal Club:
Cancer Prevention Research with Drs. Andrew T. Chan and Douglas Grossman
Moderated by: Jing Peng, PhD
Cancer Prevention Research Associate Editor
Recorded: 01/14/2022
Watch the recording of the AACR Journal Club session featuring Drs. Andrew T. Chan and Douglas Grossman, discussing their articles recently published in Cancer Prevention Research, "Association between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study" and "A randomized double-blind placebo-controlled trial of oral aspirin for protection of melanocytic nevi against UV-induced DNA damage." Dr. Chan and colleagues evaluate the association between aspirin use and risk of gastric adenocarcinoma in two large prospective U.S. cohort studies, the Nurses' Health Study and the Health Professionals Follow-up Study. They found that regular aspirin use was associated with lower risk of gastric adenocarcinoma among women, but not men. The benefit appeared after at least 10 years of use and was maximized at higher doses. The sex difference in the effect of aspirin on gastric neoplasia needs to be further investigated. Dr. Grossman and colleagues conducted a prospective randomized placebo-controlled trial to determine the impact of aspirin on biomarkers associated with UV-induced inflammation and DNA damage in melanocytic nevi. Ninety-five participants were randomized to receive placebo or aspirin (81 mg or 325 mg) daily for a month, then one control nevus and one UV-irradiated nevus were removed from each participant for biomarker analyses. Although subjects who received aspirin had reduced PGE2 levels in plasma and nevi, there was no protection against UV-induced DNA damage in nevi. Alternate dosing regimens or examination protocols could be further investigated to develop melanoma chemoprevention strategies. Stay tuned for the Q&A session at the end of the recording.
Stay tuned for the Q&A session at the end of the recording.
About the Featured Speakers:
Andrew T. Chan, MD, MPH, is a gastroenterologist, the Daniel K. Podolsky Professor of Medicine at Harvard Medical School, Professor of Immunology and Infectious Diseases at Harvard T. H. Chan School of Public Health, Chief of the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital and the Director of Epidemiology at the MGH Cancer Center.
Douglas Grossman, MD, PhD, is an investigator in the Huntsman Cancer Institute's Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is a Co-Leader of the Melanoma Center and directs the Mole Mapping Program at the Huntsman Cancer Institute.
